Skip to main content

Table 1 Demographics and clinical characteristics of 605 eligible patients before PSM

From: Perioperative blood transfusion does not affect recurrence-free and overall survivals after curative resection for intrahepatic cholangiocarcinoma: a propensity score matching analysis

Characteristic

Variable

Before PSM

No-PBT

PBT

P value

(n = 512)

(n = 93)

Age

Y ± SD

57.42 ± 10.815

56.54 ± 11.801

0.176a

Gender

female/ male

190/322

48/45

0.008c

Preoperative Hb

g/L ± SD

132.53 ± 16.22

118.63 ± 17.68

0.329a

Platelet

1 × 109/L ± SD

179.25 ± 64.02

201.30 ± 97.35

0.038a

Total bilirubin

available data

510(99.61%)

92 (98.92%)

 

umol /L ± SD

24.98 ± 55.35

86.79 ± 134.47

<0.001b

AST

available data

502(98.05%)

90 (96.77%)

 

U/L ± SD

44.56 ± 87.09

56.21 ± 57.45

<0.001b

ALT

available data

509 (99.41%)

92 (98.92%)

 

U/L ± SD

50.40 ± 95.22

57.90 ± 67.28

0.002b

AFP

available data

497 (97.07%)

91 (97.85%)

 

ng/mL ± SD

95.28 ± 953.72

93.02 ± 585.95

0.982b

CEA

available data

489 (95.51%)

87 (93.55%)

 

ng/mL ± SD

22.42 ± 154.07

61.84 ± 330.14

0.060b

CA19–9

available data

486 (94.92%)

86 (92.47%)

 

U/mL ± SD

1152.16 ± 3116.14

2698.09 ± 4923.75

<0.001b

PT

available data

506 (98.83%)

91 (97.85%)

 

s ± SD

11.20 ± 9.23

11.87 ± 3.11

0.093b

INR

available data

502 (98.05%)

89 (95.70%)

 
 

Value ±SD

0.98 ± 0.11

0.98 ± 0.14

0.910b

HBsAg

available data

506 (98.83%)

93 (100.00%)

 

(−)/(+)

302/204

71/22

0.002c

Anti-HCV

available data

502 (98.05%)

93 (100.00%)

 

(−)/(+)

493/9

91/2

0.814c

Tumor number

available data

511 (99.80%)

92 (98.92%)

 

1/>1

426/85

81/11

0.259c

TMD

available data

509 (99.41%)

93 (100.00%)

 

cm

6.48 ± 3.16

6.92 ± 3.44

0.284b

TNM stage

available data

489 (95.51%)

74 (79.57%)

 

I/II/III/IVa

294/80/17/98

47/15/0/12

0.433c

Cirrhotic nodule

available data

512 (100.00%)

91 (97.85%)

 

no/ yes

344/168

70/21

0.065c

DD

available data

412 (80.47%)

76 (81.72%)

 

I/II-III/IV

2/408/2 (0.49%)

0/76/0 (0.00%)

1.000c

IBL

available data

503 (98.24%)

93 (100.00%)

 

<1 L/≥1 L

499/4 (99.20%)

61/32 (65.59%)

<0.001c

Preventive TACE

no/yes

474/38 (92.58%)

86/7 (92.47%)

0.972c

Propensity Score

available data

501 (84.49%)

92 (15.51%)

 
  

0.096 ± 0.104

0.479 ± 0.372

<0.001b

  1. at test
  2. bK-Independent-Samples Test (Kruskal Wallis H(K) test)
  3. cTwo-Independent-Samples Test (Mann-Whitney U test)
  4. Values are presented as n (%) or mean ± standard deviation(SD)
  5. Hb: hemoglobin; AST: aspartate aminotransferase; ALT: alanine transaminase; AFP: alpha fetoprotein; CEA: carcinoembryonic antigen; CA19–9: carbohydrate antigen 19–9; PT: prothrombin time; INR: international normalized ratio; HBsAg: hepatitis B surface antigen; Anti-HCV: anti-hepatitis C virus; TMD: tumor maximum dimension; TNM: tumor node metastasis; IBL: intraoperative blood loss; DD: The degree of differentiation;
  6. TACE: transcatheter arterial chemoembolization. PSM: propensity score matching; No-PBT: no-perioperative transfusion; PBT: perioperative transfusion
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us